GlassScriptPhysician profile
Danielle Demarzo
NPI 1154521722
$1,101.58
in general payments reported to CMS, 2019-2025
13 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.76 · 2021: $208 · 2022: $148 · 2023: $295 · 2024: $83.92 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640 · Education: $35.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.20 |
| Education | $35.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $475.77 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $172.21 | 2019-2025 | Koselugo, Strensiq |
| Biomarin Pharmaceutical INC. | $111.27 | 2019-2022 | |
| Amicus Therapeutics, INC. | $70.29 | 2019-2025 | Pombiliti, Opfolda |
| Takeda Pharmaceuticals U.S.A., INC. | $53.75 | 2024-2025 | Vpriv |
| Myriad Genetic Laboratories, INC. | $49.53 | 2022 | |
| Medunik USA INC. | $39.28 | 2024-2025 | Pheburane |
| Ultragenyx Pharmaceutical INC. | $38.19 | 2023-2024 | Dojolvi |
| Ptc Therapeutics, INC. | $31.60 | 2025 | Sephience |
| Zevra Therapeutics INC | $28.46 | 2024 | Olpruva |
| Cycle Pharmaceuticals INC | $19.63 | 2025 | Javygtor, Nityr |
| Shire North American Group INC | $11.60 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Demarzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.